FarmavitaR+ Journal
Business News
Development of International OTC Bradns | Development of International OTC Bradns |
|
|
| Written by Zdravko Mauko | ||||||
| Tuesday, 08 January 2008 | ||||||
Healthcare Brands International announces the acquisition of Antula Holdings AB
Healthcare Brands International (HBI) announces the completion of a major step towards its goal of building a new international Over-the-Counter (OTC) healthcare business with the acquisition of Antula Holdings AB, the privately-owned Scandinavian OTC healthcare business, and its subsidiaries. HBI was launched in October 2006 and is led by Barry Clare, former Chief Executive of Boots Healthcare International. Its mission is to develop an international OTC healthcare business based on acquiring innovative products, with clinically-proven efficacy, that have the potential to be exploited in markets around the world.Antula is the leading independent OTC healthcare company in the Scandinavian market. Successful pharmaceutical brands such as SB12, Zon, Lactal and Eeze have contributed strongly to Antula becoming the fastest growing OTC healthcare business in its local markets over recent years. HBI is funded by an international syndicate of life science investors. The financing for this substantial acquisition was co-led by new investor Essex Woodlands, 3i and MVM, with all other existing investors Goldman Sachs, Sofinnova Partners and Abingworth also participating substantially in the transaction. The acquisition of Antula is the third transaction announced to date by HBI. Since October 2006, HBI has acquired the Sambucol brand, an elderberry extract with clinically proven efficacy for the treatment of flu, and the rights to develop and market docosanol, the leading US cold sore treatment, in products for the treatment of cold sores in Europe. Barry Clare, Chairman and CEO of HBI, believes that Antula is a highly complementary acquisition for HBI: "Antula provides us with both a business in the Scandinavian markets that has the potential to continue its proven track record of growth and an important portfolio of successful brands, some of which we plan to develop into genuine international franchises." For further information please contact: HBI Rob Morgan/Sarah Clarke, BMA Communications Tel: +44 (0) 20 8682 2482 / email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
About H.B.I. (Healthcare Brands International) http://www.healthcarebrandsinternational.com/
About Antula Healthcare
About Essex Woodlands
Essex Woodlands Health Ventures is one of
the world's largest and most established health care venture capital firms with
nearly $2 billion of capital under management.
Essex Woodlands invests world-wide in leading private companies in
pharmaceuticals, biotechnology, medical technology and health care
services. The Managing Directors of
Essex Woodlands work closely with their portfolio companies as lead investors
to build significant shareholder value over a period of several years. About 3i 3i is a world leader in private equity and venture capital. We focus on Buyouts, Growth Capital, Venture Capital, Infrastructure and Quoted Private Equity ("QPE") and invest across Europe, the United States and Asia. Our competitive advantage comes from our international network and the strength and breadth of our business relationships. These underpin the value that we deliver to our portfolio and to our shareholders.
3i's recent investments in the healthcare sector
include EUSA Pharma, TransMedics, Zonare, Small Bone Innovations and Carmel
Pharma, with successful realisations including Care Principles, Westminister
Healthcare, Clinica Baviera, Betapharm, DocMorris, and Domantis.
About MVM Life Science Partners
MVM Life Science Partners
LLP, founded in 1997, is one of the UK's leading Venture Capital firms
and manages three funds totalling US$500 million. MVM invests across the Life
Sciences market including biopharmaceuticals, diagnostics, drug delivery, gene
therapy, medical devices, OTC medicines, research tools and vaccines. MVM
invests predominantly in start up and early staged companies based across
Europe and in the US.
The MVM team has broad experience across the Life Science and Venture Capital
markets and maintains offices in London and Boston.
About Goldman Sachs
Goldman Sachs is a leading global investment
banking, securities and investment management firm that provides a wide range
of services worldwide to a substantial and diversified client base that
includes corporations, financial institutions, governments and high net worth
individuals. Founded in 1869, it is one of the oldest and largest investment
banking firms. The firm is headquartered in New York
and maintains offices in London, Frankfurt, Tokyo, Hong Kong and
other major financial centers around the world.
About Sofinnova Partners
Sofinnova
Partners is France's leading venture capital company,
specializing in early stage companies in information technologies and life
sciences in France
and other European countries. A sister
company, Sofinnova Ventures, is based in San
Francisco. In Life Sciences, Sofinnova Partners focuses on ambitious seed and
start-up projects developing new therapeutics in both biopharmaceuticals and
medical devices. Priority
is given to companies that develop new products for unmet clinical needs within
a sizeable market sector. Current
investments managed are valued at €900 million.
About Abingworth Abingworth is a long-established venture capital firm dedicated to the life sciences sector on both sides of the Atlantic. The company invests across all stages of development, including early-stage as well as public companies. Abingworth has provided backing to more than 90 life science businesses. The majority of these have gone public or have merged or been acquired. Abingworth has funds under management of more than $750 million. Founded in 1973, Abingworth has offices in London, Cambridge (UK), Menlo Park (California) and Boston.
Abingworth's
team has a strong scientific background in addition to specialist business and
financial capabilities. The skill sets
include legal, recruiting, fund raising and investment banking capabilities as
well as strong operating experience.
These resources are extended to portfolio companies to help the company
building process.
Only registered users can write comments! Powered by !JoomlaComment 3.12 Copyright (C) 2007 Alain Georgette / Copyright (C) 2006 Frantisek Hliva. All rights reserved.Related Items
|
||||||
| Last Updated ( Tuesday, 08 January 2008 ) | ||||||
| Next > |
|---|
Regulatory Affairs Support for EU and USAIn collaboration with Regulanet network of regulatory affairs consultants throughout Europe and USA, we keep daily contacts and communication with National Agencies for Medicines and Medical Devices. Beside regulatory we also maintain understanding of the business, scientific and technical background of products. |